Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Summer 2017

The Genetic Influences on Opiate Addiction
Anne Sielschott
anne.sielschott@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Nursing Commons

Recommended Citation
Sielschott, Anne, "The Genetic Influences on Opiate Addiction" (2017). Nursing Student Class Projects
(Formerly MSN). 265.
https://digitalcommons.otterbein.edu/stu_msn/265

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

The Genetic Influences on Opiate Addiction
Anne Sielschott, RN, BSN
Otterbein University, Westerville, Ohio
Introduction
The effects of addiction and the present opioid crisis can not only be felt at the individual level of
the addict but throughout all aspects of society. From the infant born addicted to heroin, to the
family members begging their loved ones to make a change, to the medical personnel with the
responsibility of caring for those with drug seeking or violent behavior needing their next fix, the
drug problem in America is one that can no longer be ignored. The number of unintentional drug
overdoses in Ohio has grown from 411 in 2000 to a staggering 3050 in 2015, currently averaging 8
deaths per day in Ohio alone (Ohio Department of Health [ODH], 2017).
It is the responsibility of medical personnel to not only be aware of the statistics and trends
regarding this crisis, but to be knowledgeable and up to date on the current research regarding
what makes an individual an addict. What differences exist, for example, between Jimmy and Sally
following knee surgery that has Jimmy returning to the emergency department with drug seeking
behavior while Sally’s bottle sits half full on the shelf. While not all aspects of the pathophysiology
behind the genetic influences of addiction are understood, much research is being completed
searching for these answers. New models have also been developed that aid the provider in the
accurate diagnosis of addiction and its associated behaviors (Belin-Rauscent, Fouyssac, Bonci, &
Belin, 2016). These models will aid the provider in the recognition of the problem and the
development of a treatment plan

Signs and Symptoms
•
•
•
•
•
•
•
•

loss of ability to control or stop
use
trouble meeting personal, social,
and work obligations
legal/financial/marital
problems
drug seeking behaviors,
spending long amounts of time
to obtain opiates
tolerance, requiring larger
doses for desired effect
withdrawal symptoms with
reduced or discontinued use
constipation
respiratory depression

nausea/vomiting
slurred speech
confusion, delayed responses
itching or flushed skin
euphoria
continual use despite negative
physical or psychological effects
•
stupor, coma, death
•
anxiety and depression
•
alienation and loss of friends
and family relationships
•
borrowing of money, selling
possessions
(National Institute on Drug Abuse,
n.d.)
•
•
•
•
•
•

Nursing Implications
The treatment of opiate addiction is a life-long battle with frequent relapses and high
morbidity and mortality rates. Due to these poor demographics, the efforts of containing
the opiate crisis are focused on preventing further addiction. Medical providers must be
educated on the risks and benefits of prescribing opiates. It is essential for prescribers to
be up to date on the current recommendations and guidelines regarding opiate use and to
only prescribe opiates to those that meet these guidelines. Being aware of the genetic
predispositions of various ethnicities or recognizing the signs and symptoms of behaviors
highly associated with various genetic alterations and addiction can aid the provider in
decision making. A thorough physical and psychiatric exam and family history should be
obtained on every patient prior to prescribing opiates to adequately assess the patient
(Kolodny et al., 2015).
Education is also key as it has been noted that more than 75% of those who abuse
prescription pain medications originally obtained the medication from a friend or family
member (Center for Disease Control [CDC], 2011). Proper education regarding the risks
associated with giving others these medications, especially to adolescents, is critical at
preventing an addiction problem. Those who use prescription pain medications that were
not prescribed to them are four to nine times more likely to abuse heroin (Martins et al.,
2016).

Underlying Pathophysiology
Opioids work by binding to opioid receptors throughout the nervous and immune systems.
Four major types of receptors have been identified and include mu (μ), kappa (κ), delta (δ) and
OFQ/N receptors. These receptors are the binding sites for endogenous peptides, specifically
enkephalins, dynorphins and endorphins. These regulate many of the important functions of the
body including pain, stress, temperature, respiratory drive, the endocrine system,
gastrointestinal motility, mood, and motivation. The most common opiates that are abused are
mu agonists. Mu receptors, when stimulated, are responsible for the “high” felt with opiate use,
feelings of euphoria, and a decrease in anxiety (Dixon et al., 2017).
The OPRM1, OPRD1, and OPRK1 genes fall into the opioid receptor category and code for their
coordinating μ, δ, and κ receptors. Genetic variations in these receptors have been studied
across various ethnicities. These studies have found links between these genetic variants and
higher risks of developing addictions and dependence (Mistry, Bawor, Desai, Marsh, & Samaan,
2014).
The opioid receptor mu 1 (OPRM1) gene encodes for the µ-opioid receptor, which is the
primary site of action for most of the commonly abused opioids. A polymorphism of the OPRM1
gene results in the replacement of asparagine residue with aspartic acid. This results in the
118G allele. Increased sensitivity to pain and a decreased response to opioid treatment are
associated with this genetic variation. Studies of those with this variant have shown that
participants with the 118G allele request higher doses of opiates for treatment of pain (Kreek et
al., 2012).
Dopamine is a powerful neurotransmitter, responsible for the positive rewards seen with
things such as finishing a full meal, sexual encounters, and receiving an award. The use of
opiates creates a large amount of dopamine to be released into the “rewards center” of the brain,
the nucleus accumbens, providing the “high” that is sought by addicts. The drug type, amount,
and route of administration have an effect on the amount of dopamine that is released, up to ten
times the normal amount seen with pleasurable experiences, thereby causing the user to seek
higher doses and better quality substances (Harvard Medical School, 2012).
Dopamine release and dopaminergic receptor expression is thought to have an association with
impulsive and novelty-seeking behavior. Genetic polymorphisms of the D2, D3, and D4
dopamine receptor genes have been targets of recent studies linked to opioid addiction. The
DRD2 rs1800497 allele has been found to be higher in those with addition. The identification of
this allele helps predict the success of methadone treatment for opiate addiction. Genetic
polymorphisms of the DRD3 and DRD4 genes have been associated with an increase in sensation
seeking and novelty seeking behaviors respectively as commonly seen in addicts (Mistry et al.,
2014).
cAMP response element binding protein (CREB) and delta FBJ murine osteosarcoma viral
oncogene homolog B (ΔFosB) are two transcription factors that have been gaining interest in the
ongoing battle against addiction. CREB is activated in the nucleus accumbens by opiates where
it acts to reduce the rewarding behavior seen with drug use. CREB increases the drive for
seeking opiates through a negative feedback system. This occurs by reducing the addict’s
sensitivity to the rewards of the drug and enhances the negative experiences observed with the
discontinuation of opiates. Target genes for CREB have been identified and are associated with
the opioid peptide dynorphin. Dynorphin impairs reward by suppressing the transmission of
dopamine to the nucleus accumbens. Addicts then seek larger, stronger doses of the drug to
overcome the tolerance that has developed (Nestler, 2013).
In contrast to CREB, ΔFosB promotes drug use through positive reinforcement where users
see an increase in sensitivity to the drug and the positive rewards of drug use. ΔFosB is encoded
by the FOSB gene on human chromosome 19. The Fos family of transcription factors are
activated during drug use and typically return to baseline levels within twelve hours. ΔFosB,
however, is unusually stabile and accumulates during repeated drug use. (Nestler, 2013). ΔFosB
heterodimerizes with Jun family proteins and translocates to the cell’s nucleus where they bind
to activator protein-1, causing gene expression. This expression, resulting in cellular and
molecular changes, results in the emergence of the phenotypical changes observed in the addict.
With short term use of opiates, the activation of ΔFosB returns to baseline quickly. With chronic
use, however, the effects of ΔFosB can be detected months later, even after discontinuation of
use. This is thought to account for the relapses that occur during treatment and rehabilitation
(Ruffle, 2014).

Significance of Pathophysiology
It is thought that genetic influences account for 40-60%
of one’s vulnerability to addiction. These, combined with
environmental influences including social, familial, work,
and financial factors, help to determine the likelihood of
addiction (National Institute on Drug Abuse, 2014). Having
a strong knowledge of the genetic factors associated with
an increased likelihood of addition can help the provider in
decision making regarding treatment options. By
identifying the genetic alterations and the effects they have
on an individual, providers have the opportunity to provide
individualized care targeted at those most susceptible to
addiction (Levran, Yuferov, & Kreek, 2012).

Image retrieved from
https://kleantreatmentcenters.com/explaining-thegenetics-of-addiction-to-your-kids/

Conclusion
Opiate addiction is a nationwide problem felt by the entire
population. The State of Ohio has taken great steps towards
containing the crisis. Prescribing guidelines have been
established by the Governor’s Cabinet Opiate Action Team
(GCOAT) that address both acute and chronic pain control.
Educational programs targeting the school age population have
also been developed (ODH, 2017). While not all is known
about the genetic influences surrounding addition, a thorough
understanding of the current knowledge and literature by
healthcare providers, combined with the actions of the state
and educational systems, has the potential to not only better
treat and rehabilitate those with an opiate addiction but to
prevent addiction before it happens.

Image retrieved from
https://www.cdc.gov/drugoverdose/epidemic/index.html
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